semaglutide mcas A newly published case series reports that GLP-1 receptor agonists (like and tirzepatide) may significantly improve symptoms in patients with mast cell activation syndrome (MCAS), even in those without diabetes or Semaglutide targets MASH molecular pathways

Employing preclinical, ex vivo, in vivo, and in vitro model systems investigators determined that GLP-1 agonists exert anti-inflammatory and immune modulating effects through their effects on macrophages (reduced interleukin [IL] 1, IL-6, tumor necrosis factor [TNF], and C-X-C motif chemokine ligand [CXCL]), T and B lymphocytes (reduced cluster of differentiation [CD] 4 cells), monocytes (increased IL-10), mononuclear cells (decreased monocyte chemoattractant protein [MCP]1, cell death protein [PD],, CD4 and CD8 T cells) [51,52,53,54,55]

Antihyper- tensive medications and the prevalence of hyperkalemia in a large health system

2023;31(XX):XXXX

The obesity approval (Zepbound) followed in November 2023

A study published in the journal Expert Opinion on Drug Safety found that patients taking compounded GLP-1s were hospitalized over two times more often than patients taking FDA-approved versions

Community rules on subreddits like r/Peptides generally prohibit direct vendor promotion precisely because it creates conflicts of interest